Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 211

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Colorectal cancer screening—optimizing current strategies and new directions

Kuipers, Ernst J., Rösch, Thomas, Bretthauer, Michael·2013·Nature Reviews Clinical Oncology
DOI 10.1038/nrclinonc.2013.12
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2013.12

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 122

  1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010). · DOI · Paper page
  2. Brandstedt, J. et al. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol. Sex Differ. 3, 23 (2012). · DOI
  3. Boyle, T., Keegel, T., Bull., F., Heyworth, J. & Fritschi, L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J. Natl Cancer Inst. 104, 1548–1561 (2012). · DOI · Paper page
  4. Kharazmi, E., Fallah, M., Sundquist, K. & Hemminki, K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 345, e8076 (2012). · DOI
  5. Brenner, H. et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 56, 1585–1589 (2007). · DOI · Paper page
  6. Kuntz, K. M. et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med. Decis. Making 31, 530–539 (2011). · DOI
  7. Quintero, E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366, 697–706 (2012). · DOI · Paper page
  8. Stoop, E. M. et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol. 13, 55–64 (2011). · DOI · Paper page
  9. Oort, F. A. et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment. Pharmacol. Ther. 31, 432–439 (2010). · DOI
  10. Hewitson, P., Glasziou, P., Watson, E., Towler, B. & Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 103, 1541–1549 (2008). · DOI · Paper page
  11. Mandel, J. S. et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N. Engl. J. Med. 343, 1603–1607 (2000). · DOI · Paper page
  12. Jørgensen, O. D., Kronborg, O. & Fenger, C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50, 29–32 (2002). · DOI · Paper page
  13. Kewenter, J., Brevinge, H., Engarás, B., Haglind, E. & Ährén, C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand. J. Gastroenterol. 29, 468–473 (1994). · DOI · Paper page
  14. Hardcastle, J. D. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348, 1472–1477 (1996). · DOI · Paper page
  15. Faivre, J. et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126, 1674–1680 (2004). · DOI · Paper page
  16. Duffy, M. J. et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int. J. Cancer 128, 3–11 (2011). · DOI
  17. Schoenfeld, P. et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N. Engl. J. Med. 352, 2061–2068 (2005). · DOI · Paper page
  18. Steele, R. J. et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 61, 576–581 (2012). · DOI
  19. Hol, L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59, 62–68 (2010). · DOI · Paper page
  20. van Rossum, L. G. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82–90 (2008). · DOI · Paper page
  21. Konrad, G. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can. Fam. Physician 56, 229–238 (2010).
  22. Levi, Z. et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am. J. Gastroenterol. 104, 933–938 (2009). · DOI
  23. Konrad, G. & Katz, A. Are medication restrictions before FOBT necessary?: practical advice based on a systematic review of the literature. Can. Fam. Physician 58, 939–948 (2009).
  24. Allard, J. et al. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline. Can. J. Gastroenterol. 24, 113–120 (2010). · doi:10.1155/2010/516363
  25. Faivre, J. et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur. J. Cancer 48, 2969–2976 (2012). · DOI
  26. Chiba, H. et al. Is it worthwhile to perform capsule endoscopy for asymptomatic patients with positive immunochemical faecal occult blood test? Dig. Dis. Sci. 56, 3459–3462 (2011). · doi:10.1007/s10620-011-1798-4
  27. Levi, Z., Vilkin, A. & Niv, Y. Esophago-gastro-duodenoscopy is not indicated in patients with positive immunochemical test and nonexplanatory colonoscopy. Eur. J. Gastroenterol. Hepatol. 22, 1431–1434 (2010).
  28. Cole, S. R., Young, G. P., Esterman, A., Cadd, B. & Morcom, J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J. Med. Screen 10, 117–122 (2003). · DOI · Paper page
  29. Hol, L. et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 100, 1103–1110 (2009). · DOI · Paper page
  30. de Wijkerslooth, T. R. et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am. J. Gastroenterol. 107, 1570–1578 (2012). · DOI · Paper page
  31. Haug, U., Hundt, S. & Brenner, H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am. J. Gastroenterol. 105, 682–690 (2010). · DOI
  32. Hundt, S., Haug, U. & Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150, 162–169 (2009). · DOI · Paper page
  33. Allison, J. E. et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J. Natl Cancer Inst. 99, 1462–1470 (2007). · DOI · Paper page
  34. Graser, A. et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58, 241–248 (2009). · DOI · Paper page
  35. Park, D. I. et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am. J. Gastroenterol. 105, 2017–2025 (2010). · DOI · Paper page
  36. van Roon, A. H. et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin. Gastroenterol. Hepatol. 9, 333–339 (2011). · DOI
  37. Levi, Z. et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int. J. Cancer 128, 2415–2424 (2011). · DOI
  38. van Roon, A. H. et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut http://dx.doi.org/10.1136/gutjnl-2011-301583 . · DOI
  39. Parente, F. et al. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province. Am. J. Gastroenterol. 106, 1986–1993 (2011). · doi:10.1038/ajg.2011.185
  40. Crotta, S. et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin. Gastroenterol. Hepatol. 10, 633–638 (2012). · doi:10.1016/j.cgh.2012.02.030
  41. Denters, M. J. et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 142, 497–504 (2012). · DOI
  42. Chen, L. S., Yen, A. M., Chiu, S. Y., Liao, C. S. & Chen, H. H. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol. 12, 551–558 (2011). · DOI
  43. Haug, U., Kuntz, K. M., Knudsen, A. B., Hundt, S. & Brenner, H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br. J. Cancer 104, 1779–1785 (2011). · DOI
  44. Brenner, H., Haug, U. & Hundt, S. Sex differences in performance of fecal occult blood testing. Am. J. Gastroenterol. 105, 2457–2464 (2010). · DOI
  45. Guittet, L., Guillaume, E., Bouvier, V. & Launoy, G. Seasonal variations of immunochemical and gaiac faecal occult blood tests. Gut 60, 423–424 (2011). · doi:10.1136/gut.2010.224535
  46. Guittet, L. et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 20, 1492–1501 (2011). · doi:10.1158/1055-9965.epi-10-0594
  47. van Roon, A. H. et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am. J. Gastroenterol. 107, 99–107 (2012). · DOI
  48. Vilkin, A. et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am. J. Gastroenterol. 100, 2519–2525 (2005). · DOI
  49. Grazzini, G. et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 59, 1511–1515 (2010). · DOI
  50. Levin, T. R. Editorial: taking FIT to the people: out of the office and into the mail. Am. J. Gastroenterol. 107, 108–110 (2012). · doi:10.1038/ajg.2011.401
  51. Fraser, C. G. et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J. Natl Cancer Inst. 104, 810–814 (2012). · DOI · Paper page
  52. Hoff, G., Grotmol, T., Skovlund, E., Bretthauer, M. & Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338, b1846 (2009). · DOI · Paper page
  53. Atkin, W. S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624–1633 (2010). · DOI · Paper page
  54. Segnan, N. et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial—SCORE. J. Natl Cancer Inst. 103, 1310–1322 (2011). · DOI · Paper page
  55. Schoen, R. E. et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366, 2345–2357 (2012). · DOI · Paper page
  56. Weissfeld, J. L. et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J. Natl Cancer Inst. 104, 280–289 (2012). · doi:10.1093/jnci/djr549
  57. Levin, B. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134, 1570–1595 (2008). · DOI · Paper page
  58. Lieberman, D. Colorectal cancer screening: practice guidelines. Dig. Dis. 30 (Suppl. 2), 34–38 (2012). · DOI
  59. Qaseem, A. et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann. Intern. Med. 156, 378–386 (2012). · DOI · Paper page
  60. Valori, R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy 44 (Suppl. 3), SE88–SE105 (2012).
  61. Hol, L. et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int. J. Cancer 130, 2096–2102 (2012). · DOI
  62. Senore, C. et al. Offering people a choice for colorectal cancer screening. Gut http://dx.doi.org/10.1136/gutjnl-2011-301013 . · DOI
  63. Kato, J. et al. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin. Gastroenterol. Hepatol. 7, 1341–1346 (2009). · doi:10.1016/j.cgh.2009.04.025
  64. Kaminski, M. F. et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 362, 1795–1803 (2010). · DOI · Paper page
  65. Stock, C., Ihle, P., Schubert, I. & Brenner, H. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. Endoscopy 43, 771–781 (2011). · doi:10.1055/s-0030-1256504
  66. Winawer, S. J. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 329, 1977–1981 (1993). · DOI · Paper page
  67. Zauber, A. G. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366, 687–696 (2012). · DOI · Paper page
  68. Robertson, D. J. et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129, 34–41 (2005). · DOI · Paper page
  69. van Rijn, J. C. et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am. J. Gastroenterol. 101, 343–350 (2006). · DOI · Paper page
  70. Ramsoekh, D. et al. A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut 59, 785–793 (2010). · doi:10.1136/gut.2008.151589
  71. Pohl, H. et al. Incomplete polyp resection during colonoscopy—results of the Complete Adenoma Resection (CARE) study. Gastroenterology 144, 74–80.e1 (2012). · DOI · Paper page
  72. Loeve, F., van Ballegooijen, M., Boer, R., Kuipers, E. J. & Habbema, J. D. Colorectal cancer risk in adenoma patients: a nation-wide study. Int. J. Cancer 111, 147–151 (2004). · doi:10.1002/ijc.20241
  73. Baxter, N. N. et al. Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 150, 1–8 (2009). · DOI · Paper page
  74. Singh, H. et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 139, 1128–1137 (2010). · DOI · Paper page
  75. Panteris, V., Haringsma, J. & Kuipers, E. J. Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy 41, 941–951 (2009). · doi:10.1055/s-0029-1215179
  76. Kaminski, M. F. et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 44, 695–702 (2012). · DOI · Paper page
  77. Rogal, S. S., Pinsky, P. F. & Schoen, R. E. Relationship between detection of adenomas by flexible sigmoidoscopy and interval distal colorectal cancer. Clin. Gastroenterol. Hepatol. 11, 73–78 (2012). · DOI
  78. Bressler, B. et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 132, 96–102 (2007). · DOI · Paper page
  79. Lebwohl, B. et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest. Endosc. 73, 1207–1214 (2011). · DOI · Paper page
  80. Armstrong, D. et al. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can. J. Gastroenterol. 26, 17–31 (2012). · DOI
  81. Jover, R. et al. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44, 444–451 (2012). · DOI
  82. Lieberman, D. A. et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143, 844–857 (2012). · DOI · Paper page
  83. Kim, D. H. et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N. Engl. J. Med. 357, 1403–1412 (2007). · DOI · Paper page
  84. Johnson, C. D. et al. Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med. 359, 1207–1217 (2008). · DOI · Paper page
  85. de Haan, M. C. et al. Comparing the diagnostic yields of technologists and radiologists in an invitational colorectal cancer screening program performed with CT colonography. Radiology 264, 771–778 (2012). · doi:10.1148/radiol.12112486
  86. Kim, D. H., Pooler, B. D., Weiss, J. M. & Pickhardt, P. J. Five year colorectal cancer outcomes in a large negative CT colonography screening cohort. Eur. Radiol. 22, 1488–1494 (2012). · doi:10.1007/s00330-011-2365-2
  87. de Wijkerslooth, T. R. et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 61, 1552–1559 (2012). · DOI
  88. Vanness, D. J. et al. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 261, 487–498 (2011). · DOI
  89. Liedenbaum, M. H. et al. Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening. Gut 58, 1242–1249 (2009). · doi:10.1136/gut.2009.176867
  90. McFarland, E. G. et al. ACR Colon Cancer Committee white paper: status of CT colonography 2009. J. Am. Coll. Radiol. 6, 756–772.e4 (2009). · doi:10.1016/j.jacr.2009.09.007
  91. Wilschut, J. A. et al. Fecal occult blood testing when colonoscopy capacity is limited. J. Natl Cancer Inst. 103, 1741–1751 (2011). · doi:10.1093/jnci/djr385
  92. Wilschut, J. A. et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 141, 1648–1655.e1 (2011). · DOI
  93. Wilschut, J. A. et al. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 117, 4166–4174 (2011). · DOI
  94. de Wijkerslooth, T. R. et al. Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. Gut 61, 1426–1434 (2012). · DOI
  95. Leufkens, A. M. et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest. Endosc. 73, 480–489 (2011). · DOI · Paper page
  96. Leung, F. W. et al. Water-aided colonoscopy: a systematic review. Gastrointest. Endosc. 76, 657–666 (2012). · doi:10.1016/j.gie.2012.04.467
  97. Adler, A. et al. Latest generation, wide-angle, high-definition colonoscopes increase adenoma detection rate. Clin. Gastroenterol. Hepatol. 10, 155–159 (2012). · DOI
  98. Eliakim, R. Video capsule colonoscopy: where will we be in 2015? Gastroenterology 139, 1468–1471 (2010). · DOI
  99. Spada, C. et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest. Endosc. 74, 581–589 (2011). · DOI · Paper page
  100. Van Gossum, A. et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N. Engl. J. Med. 361, 264–270 (2009). · DOI · Paper page
  101. Spada, C. et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin. Gastroenterol. Hepatol. 8, 516–522 (2010). · DOI
  102. Groth, S. et al. Capsule colonoscopy increases uptake of colorectal cancer screening. BMC Gastroenterol. 12, 80 (2012). · doi:10.1186/1471-230x-12-80
  103. Osborn, N. K. & Ahlquist, D. A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128, 192–206 (2005). · DOI · Paper page
  104. Bosch, L. J. et al. Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10, 8–23 (2011). · DOI
  105. Wild, N. et al. A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 16, 6111–6121 (2010). · DOI
  106. Lofton-Day, C. et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414–423 (2008). · DOI · Paper page
  107. Tóth, K. et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7, e46000 (2012). · DOI · Paper page
  108. van Roon, A. H. et al. Advance notification letters increase adherence in colorectal cancer screening: a population-based randomized trial. Prev. Med. 52, 448–451 (2011). · DOI
  109. Federici, A. et al. The role of GPs in increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy). Cancer Causes Control 17, 45–52 (2006). · DOI
  110. von Karsa, L. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction of the full supplement publication. Endoscopy 44 (Suppl. 3), SE15–SE30 (2012).
  111. Yabroff, K. R. et al. Are physicians' recommendations for colorectal cancer screening guideline-consistent? J. Gen. Intern. Med. 26, 177–184 (2011). · DOI
  112. van Dam, L., Kuipers, E. J., Steyerberg, E. W., van Leerdam, M. E. & de Beaufort, I. D. The price of autonomy: should we offer individuals a choice between colorectal cancer screening strategies? Lancet Oncol. 14, e38–46 (2013). · doi:10.1016/s1470-2045(12)70455-2
  113. Segnan, N. et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J. Natl Cancer Inst. 97, 347–357 (2005). · DOI · Paper page
  114. Inadomi, J. M. et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch. Intern. Med. 172, 575–582 (2012). · DOI · Paper page
  115. Valori, R., Sint Nicolaas, J. & de Jonge, V. Quality assurance of endoscopy in colorectal cancer screening. Best Pract. Res. Clin. Gastroenterol. 24, 451–464 (2010). · doi:10.1016/j.bpg.2010.06.006
  116. Morikawa, T. et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129, 422–428 (2005). · DOI · Paper page
  117. Gavin, D. R. et al. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 62, 242–249 (2012). · DOI · Paper page
  118. de Jonge, V. et al. A prospective audit of patient experiences in colonoscopy using the Global Rating Scale: a cohort of 1,187 patients. Can. J. Gastroenterol. 24, 607–613 (2010). · doi:10.1155/2010/724924
  119. Sint Nicolaas, J. et al. The Global Rating Scale in clinical practice: a comprehensive quality assurance programme for endoscopy departments. Dig. Liver Dis. 44, 919–924 (2012). · doi:10.1016/j.dld.2012.06.021
  120. Lansdorp-Vogelaar, I., van Ballegooijen, M., Zauber, A. G., Habbema, J. D. & Kuipers, E. J. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J. Natl Cancer Inst. 101, 1412–1422 (2009). · DOI · Paper page
  121. Tappenden, P. et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56, 677–684 (2007). · DOI
  122. Holden, D. J., Jonas, D. E., Porterfield, D. S., Reuland, D. & Harris, R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann. Intern. Med. 152, 668–676 (2010). · DOI · Paper page

Cited by

See all 211

Metadata

Authors
Kuipers, E. J., Rösch, T., & Bretthauer, M.
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2013-02-05
Volume
10
Issue
3
Pages
130-142
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
DOI
10.1038/nrclinonc.2013.12
OpenAlex
W2004955567
Cited by
211
References
1
FWCI
2.76
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colorectal cancer screening—optimizing current strategies and new directions. https://app.cochat.ai/papers/10.1038/nrclinonc.2013.12
The paper
Kuipers, E. J., Rösch, T., & Bretthauer, M. (2013). Colorectal cancer screening—optimizing current strategies and new directions. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2013.12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.